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Human T  cell leukemia virus (HTLV), which we previously called adult T  cell 
leukemia virus  (ATLV),  is  a  possible  causative agent  of human adult  T  cell 
leukemia (ATL) (1). Since the HTLV genome was demonstrated not to contain 
a  typical  v-onc  gene  (2)  and  the  HTLV  proviral  genome  is  integrated  into 
random sites in  cellular DNA  of leukemia cells  in each ATL patient (3),  the 
mechanism of HTLV-induced oncogenesis is still  unknown. The interleukin 2 
(IL-2) autocrine hypothesis can be excluded as the mechanism of ATL leuke- 
mogenesis, because the IL-2 receptor (IL-2R) was detected in all ATL leukemia 
cells and HTLV-transformed human T  cells that were examined (4), but the IL- 
2 gene was not transcribed in most of these cells (5).  However, it was reported 
(6) that expression of the IL-2R is abnormal in ATL leukemia cells because it is 
not down-regulated by anti-IL-2R (Tac) antibody, and is constitutive, while IL- 
2R expression in peripheral blood leukocytes (PBL) stimulated with concanavalin 
A is down-regulated. This observation resulted in another hypothesis, that the 
constitutive expression of the IL-2R may play a crucial role in ATL leukemogen- 
esis. Our recent observation (7) that HTLV can induce expression of the IL-2R 
on human B cell lines, strongly supports the notion that HTLV directly contrib- 
utes to  the  constitutive production of the  IL-2R on  ATL leukemia cells  and 
other HTLV-carrying human T  cells.  However, it is still unknown how the cell 
growth signal  can  be  transduced constitutively from the  IL-2R expressed  on 
ATL leukemia cells and  HTLV-transformed cell  lines.  Similarly, it has  been 
demonstrated (8)  that the A431  human epidermoid carcinoma cell line has a 
large number of receptors for the epidermal growth factor (EGF) that could be 
products of the c-erbB  gene, a  cellular oncogene, and it is suggested (8)  that 
overproduction or uncontrolled expression of  the EGF receptors could be related 
to the appearance of the transformed phenotype in the A431 cell line. 
We previously (4) obtained HTLV-carrying human T  cell lines of two distinct 
types with respect to their IL-2 dependency. One type (ILT) is IL-2 dependent; 
the  other  (TL)  is  IL-2  independent  for  in  vitro  growth.  Most  of the  IL-2- 
independent TL cell  lines arose spontaneously from IL-2-dependent ILT cell 
lines in vitro. This change from IL-2 dependence to IL-2 independence could 
be due to immortalizing transformation of the cells induced by HTLV (9,  10). 
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In the present study, to clarify the difference, if any, between the IL-2R in ILT 
and  TL  cell  lines,  we examined whether  the  TL  cell lines could be stimulated 
further by IL-2. Results showed that in vitro growth of TL cell lines was markedly 
inhibited by IL-2, suggesting that the IL-2R of TL cell lines mediates directly in 
transducing the signal for continuous cell growth. The roles of IL-2R in HTLV- 
induced transformation and leukemogenesis of human T  cells are discussed. 
Materials and  Methods 
Cell Lines.  The HTLV-carrying cell lines used were established as reported previously 
(4). Cell lines, TL-Mor, TL-TerI, and TL-Su, were selected for IL-2-independent growth 
from the IL-2-dependent cell lines ILT-Mor, ILT-TerI, and ILT-Su, respectively. The 
TL-OmI cell line was also an IL-2-independent cell line established directly from PBL of 
an ATL patient.  TL cell lines were maintained in  RPMI  1640  medium supplemented 
with 20% fetal calf serum (FCS).  ILT cell lines were maintained in RPMI 1640 medium 
supplemented  with  20%  FCS  and  50  U/ml  of recombinant  IL-2.  The  other  HTLV- 
carrying T  cell  lines  used  were  MT-1  (11),  MT-2  (9),  and  TCL-As2 (4).  An  HTLV- 
carrying B cell line, LCL-KanCI, was prepared as reported previously (7). 
Cell  Growth  Curves.  Samples of 1 ×  106 cells were suspended in 5 ml of appropriate 
medium in flasks with 7% CO2.  Viable cells were counted by dye exclusion staining, and, 
when the medium was changed every 2 to 3 d  by centrifugation,  the cell number was 
readjusted to 1 x  106 or less in 5 ml of fresh medium. Cell growth curves are represented 
as total cell numbers of cultures. 
IL-2.  Recombinant human  IL-2 was obtained  from Shionogi  Co., Japan,  and  IL-2 
prepared from a concanavalin A-treatedJurkat cell culture was obtained from Ajinomoto 
Co., Japan.  Native  IL-2 was  prepared  from the  culture  fluid  of phytohemagglutinin- 
treated human spleen cells as reported previously (12).  IL-2 activities were assayed and 
units of activity were calculated by the method reported by Suzuki et al. (13). 
Antibodies.  Mouse  monoclonal  antibodies  H-31  and  F10  were  used.  H-31  (IgG1) 
antibody is against human IL-2R and can completely block the binding of IL-2 to IL-2R- 
positive cells, l F10 (IgG1) antibody is against HTLV gp21 (14). 
Results 
Four HTLV-carrying cell lines, TL-Mor, TL-OmI, TL-Su, and TL-TerI, were 
cultured  in  the  presence  or  absence  of 50  U/ml  of recombinant  IL-2.  Their 
growth curves are  shown  in  Fig.  1 A.  Growth  of TL-Mor cells  was completely 
inhibited  in the  IL-2-containing culture after cultivation for 4  d, and no viable 
cells  were  detectable  on  day  10.  Growth  inhibition  of TL-OmI  cells  was  also 
observed after culture  with IL-2 for 7  d.  Moreover, the growth rates of TL-Su 
and TL-TerI cells were lower in the presence than in the absence of IL-2 after 
cultivation for 5 d. TL-OmI, TL-Su, and TL-TerI cells maintained viability for 
at least a  further 2  wk in the presence of IL-2, although they did not grow. 
The dose response of the growth inhibitory effect of IL-2 was examined. The 
growth curves of TL-Mor cells and ILT-Mor cells, which are the parental strain 
of TL-Mor cells, were measured in the presence of various doses of recombinant 
IL-2 (Fig. 2A). The proliferation of ILT-Mor cells depended on the dose of IL- 
2,  with  the  critical  dose being  5  U/ml.  Growth  of TL-Mor cells was markedly 
inhibited  by 5  U/ml  IL-2 after cultivation  for  6  d,  and  growth  inhibition  was 
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FIGURE  1.  Effect of IL-2 on growth of various HTLV-carrying cell lines. Cells were cultured 
in the absence (O) or presence of 50 (0) and 500 (A) U/ml of recombinant IL-2. 
observed after only 4 d  with IL-2 at >50  U/ml.  Growth inhibition of TL-TerI 
cells was also dependent on the IL-2 dose, whereas that of their parental  ILT- 
TerI cells was not affected by IL-2 (Fig. 2A). >50 U/ml of IL-2 also seems to be 
effective for growth inhibition  of TL-TerI  cells. Growth inhibition  of TL-Mor 
cells was also induced by medium containing  native IL-2 derived from human 
spleen cells treated  with phytohemagglutinin  or Jurkat  cells (data  not shown). 
On the other hand, several HTLV-transformed T  cell lines tested were resistant 
to  growth  inhibition  by IL-2.  Three  HTLV-transformed  T  cell  lines,  MT-1, 
MT-2,  and  TCL-As2,  and  an  HTLV-carrying  B  cell  line,  LCL-KanCI,  were 
cultured in the presence or absence of IL-2, and their growth curves are shown 
in Fig.  1B. Up to 500 U/ml of IL-2 did not affect growth of these cell lines. 
The  specificity  of the  cell  growth  inhibition  by  IL-2  was  examined  with 
monoclonal antibody to the IL-2R. Fig. 2B shows that the inhibition of TL-Mor 
cell  growth  in  the  presence  of  IL-2  was  blocked  by addition  of anti-IL-2R 
antibody, H-31, which can inhibit binding of IL-2 to receptors, while anti-gp21 
antibody F10, as a  control,  did not block the growth-inhibiting  effect of IL-2. 
These results indicate that cell growth inhibition is caused by specific binding of 
IL-2 to the IL-2R on the TL cells. 
Discussion 
The present study demonstrates that growth of four HTLV-carrying TL cell 
lines was inhibited in the presence of IL-2. TL-Mor cells seemed to be the most 
sensitive of these lines to growth inhibition by IL-2. The inhibiting mechanism 
was based on IL-2 binding to IL-2R on the cell surface, since anti-IL-2R, which 
completely blocks IL-2 binding to the IL-2R, also prevented the growth-inhibit- 
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FiGURe; 2.  (A) Dose response effects of IL-2 on cell growth. TL-Mor, ILT-Mor, TL-Terl, 
and ILT-TerI cells were cultured in the presence of 0 (O), 0.5 (I), 5 (&), 50 (@), or 500 (A) 
U/ml of IL-2. (B) Effect ofanti-IL-2R (H-31) monoclonal antibody on inhibition of growth by 
IL-2. TL-Mor cells were cultured in medium containing 50 U/ml of IL-2 and 25% of H-31 
supernatant (@) or F10 supernatant (O) as a control. 
parental ILT cells by selection for autonomous growth without IL-2, the growth 
signal is probably continuously transduced from the IL-2R, without IL-2 binding 
in  these  TL cells.  However, the  mechanism  of this  continuous transduction  is 
unknown. The growth inhibition of TL cells by IL-2 could be due to disturbance 
of the ability of the IL-2R to transduce the growth signal.  On  the other hand, 
we did not observe significant growth inhibition mediated by IL-2 in cultures of 
HTLV-transformed MT-1,  MT-2, and  TCL-As2,  or of an  Epstein-Barr virus- 
transformed HTLV-carrying B  cell line,  LCL-KanCI, which also expressed the 
IL-2R. In those cell lines that are resistant to the growth-inhibiting effect of IL- 
2, cell growth signals could bypass the IL-2R or could start beyond the IL-2R. 
Thus,  we  suppose  that  there  are  at  least  three  phases  of cell  transformation 
induced  by  HTLV  in  vitro.  In  the  first phase,  cells infected  with  HTLV  are 
induced to express the  IL-2R, as demonstrated previously (7) in human  B  cell 
lines, and they respond to the growth-stimulating effect of IL-2, as in ILT cell 
lines. In the second phase, cells acquire autonomous growth ability, as in TL cell 
lines that are sensitive to the growth inhibiting effect of IL-2. In the third phase, 
cells such as MT-1  become able to proliferate despite the presence of IL-2. We 
found previously (unpublished data) that ATL leukemia cells can hardly prolif- 
erate  in  the presence of IL-2 during  short-term  cultivation,  and  we  found by 
karyotyping that  all  the  IL-2-dependent  T  cell  lines  established  from  PBL of 
ATL  patients  during  long-term  cultivation were derived from normal  T  cells 
(unpublished data). Thus, the situation of ATL leukemia cells seems to be similar 
to that of the TL cell lines in which growth was inhibited by IL-2. 
The growth of epidermoid carcinoma cell lines such as A431 is also suppressed 
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bearing primary epidermal ceils (17).  These observations seem very similar to 
the present  observations on  the  interaction  between  IL-2  and TL cells.  The 
mechanism of cell growth inhibition by EGF is not yet fully understood. It has 
been  suggested  (18)  that  the  growth-inhibiting effect of EGF  on  A431  cells 
results  from  the  large  number  of EGF  receptors  that  show  tyrosine-specific 
protein kinase activities, because variants of A431, which were resistant to the 
growth-inhibiting effect of EGF, had fewer EGF receptors and these receptors 
showed lower EGF-stimulated protein kinase activity than those of the parental 
A431 cells.  It was also reported (19) that EGF at low (picomolar) concentrations, 
which possibly bind to high affinity EGF receptors, stimulated A431  prolifera- 
tion, whereas higher (nanomolar) concentrations of EGF inhibited A431  prolif- 
eration.  However, in the present study, although high Concentrations of I L-2 
(>50  U)  inhibited growth  of TL  cells,  low  concentrations (<0.5  U)  did  not 
stimulate cell growth. Moreover, we could not detect any significant difference 
in the affinities or numbers of the IL-2R on HTLV-transformed T  cell lines that 
were sensitive and resistant to the growth-inhibiting effect of IL-2.  2 Furthermore, 
we have not found IL-2R to be associated with protein kinase activity. Thus, we 
have no critical evidence to explain the inhibiting mechanism of IL-2 on  cell 
growth. Since HTLV-carrying T cell lines such as HUT 102 are known to express 
more IL-2R than normal activated T  cells (20), high concentration of IL-2R may 
be necessary for growth inhibition induced by IL-2 in certain types of HTLV- 
transformed T  cell lines, such as TL. We have obtained a  variant of TL cells 
that became resistant to growth inhibition by IL-2 during cultivation in  IL-2- 
containing medium. These various HTLV-carrying, IL-2R-positive cell lines and 
their variants should be useful in studies on the mechanism of transduction of 
the cell growth signal from the IL-2R. 
Summary 
Four human T  cell lines, TL-Mor, TL-Su, TL-TerI, and TL-OmI, carrying 
human T  cell  leukemia virus (HTLV),  were  established previously. TL-Mor, 
TL-Su, and TL-TerI were derived from interleukin 2 (IL-2)-dependent parental 
cell lines cloned from peripheral blood leukocytes (PBL) of three healthy HTLV 
carriers, while TL-OmI was directly established from PBL of a patient with adult 
T  cell  leukemia.  These  four TL cell  lines  grow autonomously without  IL-2. 
When they were cultured in the presence of IL-2, their growth was  inhibited 
after a few days. This growth inhibition depended on the dose of IL-2, and the 
effective dose significantly promoted growth of their parental  IL-2-dependent 
cell lines. The growth inhibition is demonstrated to be due to specific binding of 
IL-2 to receptors on the TL cells. 
Received for publication 17January 1985. 
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